Evidence map›Paper›PMID 40063187›Full record

ArticleInflammopharmacology2025

Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.

Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mutian Niu *School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Xiaolong Li *School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Mingzhao LiSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Fangru ChenDepartment of Dermatology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, People's Republic of China.
Hui CaoDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Qingbo LiuSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Bin LiangSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Guangyu PanSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China.
Chengqin LiangSchool of Pharmacy, Guilin Medical University, Guilin, 541199, People's Republic of China. cqliang@glmc.edu.cn.
Jintao GaoSchool of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, 541199, Guangxi, People's Republic of China. jintao_gao@glmc.edu.cn.ORCID http://orcid.org/0000-0002-3991-9706

Funding

Guangxi Science and Technology Base and Talent Special Project GuikeAD20238051Innovation Project of Guangxi Graduate Education YCSW2023420National Natural Science Foundation of China 31860314National Natural Science Foundation of China 32360167Natural Science Foundation of Guangxi Zhuang Autonomous Region 2016GXNSFBA380146Natural Science Foundation of Guangxi Zhuang Autonomous Region 2018GXNSFAA281041
6 · The paper itself

Abstract

Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.

Indexed as

KeratinocytesProto-Oncogene Proteins c-aktPsoriasisSesquiterpenesAnimalsAnti-Inflammatory AgentsCell ProliferationCytokinesDisease Models, AnimalHaCaT CellsHumansImiquimodInflammationMicePhosphatidylinositol 3-KinasesSignal TransductionAnti-Inflammatory AgentscurcumolCytokinesImiquimodPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSesquiterpenesCurcumolInflammationKeratinocytesProliferationPsoriasis

Identifiers

PMID40063187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.